Analyst Estimates: Here's What Brokers Think Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) After Its Third-Quarter Report

Last week saw the newest third-quarter earnings release from Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013), an important milestone in the company's journey to build a stronger business. Revenues came in 2.3% below expectations, at ر.س3.5b. Statutory earnings per share were relatively better off, with a per-share profit of ر.س1.72 being roughly in line with analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the ten analysts covering Dr. Sulaiman Al Habib Medical Services Group are now predicting revenues of ر.س16.3b in 2026. If met, this would reflect a major 24% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 31% to ر.س8.87. Before this earnings report, the analysts had been forecasting revenues of ر.س16.3b and earnings per share (EPS) of ر.س8.95 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

Check out our latest analysis for Dr. Sulaiman Al Habib Medical Services Group

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ر.س297. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Dr. Sulaiman Al Habib Medical Services Group at ر.س330 per share, while the most bearish prices it at ر.س215. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Dr. Sulaiman Al Habib Medical Services Group shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Dr. Sulaiman Al Habib Medical Services Group's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 16% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 12% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Dr. Sulaiman Al Habib Medical Services Group to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ر.س297, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Dr. Sulaiman Al Habib Medical Services Group analysts - going out to 2027, and you can see them free on our platform here.

Even so, be aware that Dr. Sulaiman Al Habib Medical Services Group is showing 2 warning signs in our investment analysis , and 1 of those shouldn't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.